Skip to main
GUTS

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health Inc's focus on transforming metabolic disease treatment into durable, disease-modifying therapies is backed by significant market trends, as evidenced by a staggering 587% increase in prescriptions for GLP-1 drugs from 2019 to 2024. The company's upcoming FIH Phase 1 trial and anticipated scalable manufacturing capabilities suggest robust growth potential, particularly in response to the notable increase in prescriptions for GLP-1 therapies among individuals without a T2D diagnosis, which surged by approximately 1,961%. Furthermore, positive clinical data indicating improved blood glucose control and a favorable lipid profile position Fractyl Health to capitalize on the expanding market for innovative diabetes and obesity treatments, reflecting a strong foundation for future financial performance.

Bears say

Fractyl Health faces significant challenges regarding its cash burn rate, which could increase due to the expansion of its development and commercial programs, thus raising concerns over its ability to secure sufficient capital for ongoing platform development. The company's therapeutic approach remains hindered by the fundamental physiological challenges associated with type 2 diabetes (T2D), including a gradual loss of β-cell function that diminishes the effectiveness of their treatments. Additionally, research indicates potential inefficacies in its GLP-1 related therapies, with significantly lower circulating levels compared to pharmacologic alternatives, which may compromise the company's long-term viability and investor confidence.

GUTS has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Strong Buy based on their latest research and market trends.

According to 4 analysts, GUTS has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.